Business Context and Reporting Period
This Form 8-K, filed on September 22, 2022, reports on Mana Capital Acquisition Corp. (the "Company"), a special purpose acquisition company (SPAC) in the process of a business combination with Cardio Diagnostics, Inc. Upon completion of the merger, the Company will be renamed Cardio Diagnostics Holdings, Inc. The filing details a specific event occurring on September 21, 2022, regarding the extension of the deadline to consummate the initial business combination.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data for the reporting period. The only specific financial metric disclosed relates to a transaction to extend the SPAC's existence:
- Extension Payment: $216,667 loaned by Cardio Diagnostics, Inc. to Mana Capital.
- Debt Instrument: A promissory note issued by Mana Capital to Cardio Diagnostics in the aggregate principal amount of $216,667.
- Trust Account: The extension payment was deposited into the Company's trust account.
Other metrics such as revenue, margins, and total liquidity are not provided in this document.
Material Changes
The primary material change reported is the extension of the time available to consummate the business combination:
- Extension Period: The deadline was extended by one month, from September 26, 2022, to October 26, 2022.
- Extension Status: This represents the second of up to twelve one-month extensions permitted under the Company's Amended and Restated Certificate of Incorporation.
- Transaction Mechanism: The extension was funded by a loan from the target company, Cardio Diagnostics, rather than by shareholder contributions.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or revenue outlook. Management commentary is limited to the procedural announcement of the extension and the execution of the promissory note. The document includes a comprehensive "Forward-Looking Statements" section highlighting significant risks, including:
- Failure to satisfy closing conditions or obtain stockholder approval for the Business Combination.
- Potential termination of the Merger Agreement.
- Disruption of current plans and operations due to the merger process.
- Inability to list the post-acquisition company on the Nasdaq Stock Market.
- Impact of the COVID-19 pandemic on the combined company's business.
- Uncertainty regarding Cardio Diagnostics' ability to increase market penetration and meet projected financial results.
Investor Verification Checklist
- Verify the terms of the promissory note filed as Exhibit 10.1, including interest rates and repayment conditions.
- Review the Form S-4 registration statement for detailed information on the proposed Business Combination and proxy solicitation.
- Confirm the status of the remaining eleven potential one-month extensions available under the Certificate of Incorporation.
- Monitor the October 26, 2022, deadline for the consummation of the merger or further extension announcements.
- Assess the financial health of Cardio Diagnostics, Inc., as they are providing the funding for the extension.